AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 171 min read$HIMS

Chi Michael sold $442K of HIMS

Chi Michael (Chief Operating Officer) sold 14,027 shares of Hims & Hers Health, Inc. (HIMS) at $31.50 ($0.44M total) on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chi Michael
Published Jun 17, 2026, 10:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 10:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$HIMS
Neutral
medium confidence
Mentioned
$HIMS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HIMSNeutralLow
01

Why it matters

The only new information is the COO’s scheduled open-market sale details (shares, price, total value) under a 10b5-1 plan; no business or financial guidance changes are provided.

02

Market read

This is a routine insider-sale filing; it may slightly influence sentiment but lacks fundamental catalysts.

03

What to watch

Traders may over-weight insider sales; without accompanying buys, guidance changes, or operational news, the signal is usually weak.

Relevance 3/10Novelty 6/10Timing: SEC Form 4 filed today (2026-06-17)

Background

The article is an SEC Form 4 insider transaction disclosure for Hims & Hers Health, Inc.

Company-level read

Ticker impact

$HIMSNeutralMedium confidence
Context

Hims & Hers Health COO Chi Michael sold 14,027 shares in an open-market transaction at $31.50 on a 10b5-1 plan filed today.

Expected impact

Likely limited/short-lived impact; any move would be small unless accompanied by other catalysts.

Evidence & confidence

The filing is a primary-source Form 4, but the article provides no new fundamentals—only a scheduled insider sale size and price.

Market effects

Sector

Minimal; routine insider sale does not change sector fundamentals.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • public_company
    Hims & Hers Health, Inc.

    Issuer of the Form 4 insider sale by COO Chi Michael.

  • insider
    Chi Michael

    Chief Operating Officer who sold 14,027 shares at $31.50 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HIMS insider trading history →

Related articles

SEP 3
$HIMSHighAI 8/10

Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS

Hims & Hers Health (HIMS) faces a securities class action lawsuit following an FTC complaint alleging misconduct, including improper sharing of health data and deceptive billing practices. The FTC's lawsuit caused HIMS shares to drop 14.7% on July 29, 2026, erasing $970M in market cap. The lawsuit claims HIMS misled investors about its business practices and internal controls.

prnewswire.com2 min
SEP 2
$HIMSMed

HIMS Stock Kicks Off September In The Red: FDA’s GLP-1 Alert Steals The Spotlight From Australia Expansion

Hims & Hers Health (HIMS) stock fell 4% to $28.44 on Tuesday after the FDA issued a warning about unapproved GLP-1 weight-loss drugs. The company expanded into Australia but faces profitability pressures due to higher costs of approved GLP-1s. HIMS reported $753M revenue and an $86M net loss in Q2, raising its 2026 revenue forecast to $3.1B-$3.3B.

stocktwits.com2 min
AUG 31
$HIMSMed

Hims & Hers launches weight-loss drugs in Australia

Hims & Hers Health Inc (HIMS) launched GLP-1 weight-loss drugs and other treatments in Australia via its Pilot platform. The company acquired Eucalyptus, an Australian digital health platform, earlier in 2026. Hims aims to expand its services and targets $6.5 billion in revenue by 2030, though international growth has impacted gross margins. According to the company, international business has increased subscriptions and monthly revenue per subscriber by 21% year-over-year.

investing.com2 min
AUG 29
$HIMSMed

Dow, S&P 500, Nasdaq Futures Rise After Trump Says US-Iran War ‘Very Close To Over:’ Why HIMS, MSFT, RUM, NFLX, XNDU Are Trending After-Hours

U.S. stock futures rose after President Trump stated the U.S.-Iran war is 'very close to over.' The S&P 500 and Nasdaq Composite closed at record highs. HIMS surged 24% on FDA news, MSFT gained on AI sentiment, RUM hit a month high, NFLX rose ahead of earnings, and XNDU had its best day. Oil steadied near $91/barrel.

stocktwits.com2 min
AUG 28
$HIMSHighAI 8/10

Hims & Hers (HIMS) CEO Says the FTC Doesn’t Understand His Own Company

Hims & Hers (HIMS) CEO Andrew Dudum defended the company against an FTC lawsuit, citing its revenue growth and subscriber base. Q2 revenue rose 40% YoY to $753M, with a full-year forecast of $3.1B-$3.3B. However, margins fell to 64% from 76%, and free cash flow was negative $68M, raising concerns about profitability and legal risks.

yahoo.com2 min
AUG 28
$INTCHighAI 8/10

Why Are Nasdaq, Dow Futures Trading Mixed Premarket? INTC, SLS, SPCX, RKLB, ASTS, RIOT, FRMI Stocks Are In Focus

U.S. stock futures were mixed on Tuesday, with Nasdaq and Russell 2000 futures up 0.1%, Dow futures down 0.1%, and S&P 500 futures flat. Investors await July CPI data and geopolitical tensions impact sentiment. Key earnings reports include SMCI, CRWV, CAVA, LITE, and SLS. NVDA labeled AI data centers as investable assets, INTC upsized its share sale to $20B, and RIOT secured a $9.1B deal. RKLB shares fell despite a revenue beat, ASTS extended selloff, and SPCX faced lockup expiration pressures.

stocktwits.com3 min